Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06549231 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

Study acronym: EVER-ILD 3
StatusRecruiting
PhasePhase 3
Started2025-01-08
View on ClinicalTrials.gov ↗

Amendment history

2026-06-10
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2028-05-15→2028-07-08
Completion date2028-11-15→2029-01-08
Start dateestimated 2024-11-15→confirmed 2025-01-08
2024-08-07
Original filing
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at high risk of progression.
Trial Details
NCT Number NCT06549231
Lead Sponsor University Hospital, Tours
Conditions Interstitial Lung Disease With Systemic Sclerosis
Enrollment 102 participants
Start Date 2025-01-08
Primary Completion 2028-07-08 (estimated)
Study Completion 2029-01-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-12